Woodstock, GA -- (ReleaseWire) -- 06/22/2018 -- As the ENFit transition continues across the globe, NeoMed is ready and willing to support and facilitate hospital and healthcare facility transitions to ENFit (ISO 80369-3). To ensure a smooth and seamless conversion, NeoMed has created the ENFit Transition Support Program, designed specifically to assist Premier members during their switch to ENFit. NeoMed developed this rebate program not only to incentivize Premier members to switch to NeoConnect®, but also to confirm NeoMed's unwavering commitment to support a smooth ENFit transition from hospital to home.

Select NeoConnect products on Premier contract PP-NS-1099 are eligible for a rebate. Premier members may take advantage of this exclusive program with the acceptance of a NeoMed NeoConnect Loyalty or Transition Agreement. All purchases of select NeoConnect product made before the December 31, 2018 program expiration are eligible for rebates. Members that convert to NeoConnect on or before August 31, 2018 will earn a 5 percent rebate, while members that convert between September 1 and December 31, 2018, will earn a 2.5 percent rebate based on total purchase of NeoConnect product.

"We recognize that shifting to a new enteral safety system may seem like a big undertaking. This program is our way of demonstrating our ongoing support, while helping off-set the cost associated with transitioning to comply with the ISO 80369-3 standard," stated by Vice President of Business Development, Marc Waldman.

If you have any questions about the Premier ENFit Transition Support Program, please contact your Regional Account Manager or call 770-516-2225.

About NeoMed, Inc.
Founded in 2007, NeoMed develops innovative enteral collection and delivery products supporting the specialized feeding and medication dosing needs of the low birth weight, neonatal, and pediatric patients. With 231 successful ENFit transitions representing over 16 million administered feed and medication doses, NeoMed is committed to improve patient outcomes through product designs that meet safety, clinical, and regulatory guidelines while supporting cost-containment objectives. NeoMed is an approved Premier ENFit supplier under agreement PP-NS-1099 and PP-DI-1469.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Woodstock, GA -- (ReleaseWire) -- 04/17/2018 -- NeoMed is pleased to announce the launch of the new NeoConnect DoseMate DL (Directional Long) – an innovative and ergonomic solution for gentle, direct oral medication administration with an ENFit syringe. This new, patent-pending pharmacy accessory is ideal for dosing oral medications directly to the patient's cheek or back of the mouth.

The soft, pliable cannula features a smooth, rounded tip, which is optimal when administering oral medication into a patient's mouth. Not only does the inventive design mitigate concerns over placing threaded syringe tips into a patient's mouth, it also provides patient comfort during direct oral administration without introducing a choking hazard.1

Dosing accuracy is a key component of the DoseMate DL design. Similar to its DoseMate counterpart, the DoseMate DL minimizes priming volume and helps prevent fluid accumulation in the syringe's moat, which complies with the Global Enteral Device Supplier Association's (GEDSA) August 2016 position statement.

Ben Davis, Vice President of Engineering and Product Development, said, "Not only does the DoseMate DL satisfy a clinical need not previously addressed with other ENFit systems, but it also represents an improvement in care compared to what was available with legacy systems."

"The addition of the DoseMate DL to our ENFit accessories portfolio contributes to our mission of supporting the specialized feeding and medication dosing needs of the low birth weight, neonatal, and pediatric patient populations. We are very pleased to release a new product focused on patient comfort, while following clinical best practices. The DoseMate DL is yet another effective accessory that will help minimize protocol changes for clinicians as the global transition to ENFit continues," stated NeoMed President, Aaron Ingram.

For ordering information, contact your local sales representative, visit www.neomedinc.com, or call 888-876-2225.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Woodstock, GA -- (ReleaseWire) -- 04/16/2018 -- U.S. News and World Report recently ranked the fifty leading U.S. children's hospitals specializing in pediatric neonatology in their annual Best Children's Hospitals rankings report. NeoMed® is proud to report that four of the top five highest-ranked pediatric neonatology hospitals in the U.S. rely on NeoMed products to deliver nutrition to the most fragile patients.

The fifty pediatric centers were ranked for care of fragile newborns. The scores consisted of data, including breast milk at discharge, 30-day readmission and patient volume, along with other data from a clinical survey of children's hospitals. The remaining portion of the score was based on nominations and recommendations from pediatric specialists.

NeoMed's Vice President of Business Development, Marc Waldman, stated, "Our ENFit® and Legacy product portfolios are meticulously designed with specific features in place to help improve the outcome of the neonatal patient. We design our products with the tiniest, most fragile patient in mind, and I believe that this concept continues to resonate with NICU departments and pharmacies around the world."

Founded in 2007, NeoMed develops innovative enteral collection and delivery products supporting the specialized feeding and medication dosing needs of the low birth weight, neonatal, and pediatric patients. We are committed to improve patient outcomes through product designs that meet safety, clinical, and regulatory guidelines while supporting cost containment objectives.

Visit NeoMed® website here: https://www.neomedinc.com.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Woodstock, GA -- (ReleaseWire) -- 09/06/2017 -- NeoMed, Inc. announces the launch of the "NeoConnect® Certification Program for ENFit®." The curriculum was developed as an essential resource to assist NeoMed customers during the global transition to ENFit. The NeoConnect Certification Program is designed for clinicians to demonstrate and document clinical competency with managing the use of ENFit products to enhance patient outcome by addressing essential topics such as: Compliance with GEDSA Guidelines to administer low volume doses using the Low Dose Tip Syringe, Impact of the moat during small volume doses to preserve dose accuracy, Identifying protocol changes, Maintaining current processes, Characterizing successful facility transitions, Enhancing productivity, Maximizing Ease of Use and Feeding tube hub cleaning procedures that support ASPEN recommendations.

NeoConnect® Certification is achieved after clinicians undergo ENFit product, procedure, and simulation training. Post-training testing helps ensure that participants possess the knowledge base to train other clinicians and health care professionals as the industry transitions to ENFit. NeoMed has implemented over 60 successful ENFit conversions, representing an estimated 2,600,000 delivered enteral and medication administrations.

In preparation for this ongoing clinical project, NeoMed completed NeoConnect Certification Training for its domestic Sales Organization during the NeoMed National Sales Meeting recently held in Atlanta, Georgia. This will allow the entire sales team to assist clinicians with this important implementation initiative.

Aaron Ingram, NeoMed President, states "NeoMed's Certification Program is fundamental to driving a successful transition by helping ensure clinical understanding of work flow processes and the necessity of ENFit competency during the transition to ENFit. It provides customers with the documented expertise and the skill set required to support conversions to ENFit."

Over 7,000 U.S. hospitals are preparing for the transition to ENFit. NeoMed has developed a number of additional programs, such as the "NeoMed Transition Program," that help navigate this global conversion. Collectively, these programs help to identify hospital staff training needs, establish, and review process protocols, and ensure supply chain integrity before conversion.

NeoMed develops innovative enteral collection and delivery products supporting the specialized feeding and medication dosing needs of the low birth weight, neonatal, and pediatric patients. We are committed to improve patient outcomes through product designs that meet safety, clinical, and regulatory guidelines while supporting cost containment objectives.

About NeoMed
NeoMed offers a full portfolio of neonatal catheters and kits, metric only oral syringes in both clear and amber, urinary drainage catheters, and kits, umbilical catheters, insertion kits, and breast milk tubes.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

NeoMed receives FDA 510(k) clearance for its Low Dose Tip ENFit Syringe

Woodstock, GA -- (ReleaseWire) -- 08/29/2017 -- NeoMed, has received FDA 510(k) clearance for our NeoConnect Low Dose Tip (LDT) Oral/Enteral ENFit Syringes. NeoMed's LDT ENFit Syringes, when used as intended, achieve accurate low dose Oral Medication delivery while minimizing the risk of misconnections.

The LDT technology will be available on NeoMed's 0.5 mL, 1 mL, 3 mL and 6 mL ENFit syringes. The addition of the LDT technology completes NeoMed's full portfolio of ENFit syringes in advance of the July 2016 California legislative mandate for all hospitals to provide a dedicated safety enteral system.

This FDA 510(k) clearance also included direct oral administration indications for use of all NeoConnect syringes with ENFit connectors. The ability to utilize a NeoConnect syringe (low dose or standard) for both oral and enteral delivery of fluids means that a facility will not have to maintain a separate inventory of legacy oral syringes once they transition to ENFit.

NeoMed developed the low dose tip design, which is now being adopted by industry, and has offered all syringe manufacturers royalty free access to the design. This 510(k) clearance is a critical milestone for the clinical community to support the launch of ENFit products.

The NeoConnect family of ENFit products addresses recommendations from industry leaders such as GEDSA, ISMP, the Joint Commission, ASHP, and ASPEN.

About NeoMed
NeoMed offers a full portfolio of neonatal catheters and kits, metric only oral syringes in both clear and amber, urinary drainage catheters, and kits, umbilical catheters, insertion kits and breast milk containers.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm